Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study
David Lang,1,2 Wolfgang Haslinger,2 Kaveh Akbari,2,3 Mario Scala,2,3 Benedikt Hergan,2,3 Christian Asel,2,3 Andreas Horner,1,2 Romana Wass,1,2 Elmar Brehm,1,2 Bernhard Kaiser,1 Bernd Lamprecht1,2 1Johannes Kepler University Hospital, Department of Pulmonology, Linz, Austria; 2Johannes Kepler Univers...
Saved in:
Main Authors: | Lang D, Haslinger W, Akbari K, Scala M, Hergan B, Asel C, Horner A, Wass R, Brehm E, Kaiser B, Lamprecht B |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2020
|
Subjects: | |
Online Access: | https://doaj.org/article/de62df45ecee46c7bf7642e198ce9c9e |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of Patient Age on Clinical Efficacy and Toxicity of Checkpoint Inhibitor Therapy
by: Selina K. Wong, et al.
Published: (2021) -
Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
by: Anwen Xiong, et al.
Published: (2021) -
Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Literature Review
by: Zoe Apalla, et al.
Published: (2021) -
Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study
by: Xiaozhun Huang, et al.
Published: (2021) -
Hodgkin lymphoma. ASCO, EHA and ASH 2020 news
by: Elena A. Demina
Published: (2021)